



For information about treatment decisions and tolerability, refer to:

- Positive cardiometabolic health resource from NICE: <https://www.nice.org.uk/guidance/cg178/resources/endorsed-resources-lester-uk-adaptation-positive-cardiometabolic-health-resource-pdf-720879384517>
- The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. *Am J Psychiatry*. 2020 Sep 1;177(9):868-872. doi: 10.1176/appi.ajp.2020.177901
- Kishimoto T, et al. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. *Lancet Psychiatry*. 2021 May;8(5):387-404. doi: 10.1016/S2215-0366(21)00039-0.